Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04365764
  4. Details
NCT04365764 Clinical Trial

Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

Covid-19 Clinical Trial

Official title:
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04365764
Other study ID # CIC1421-20-06
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 14, 2020
Est. completion date December 31, 2022

Study information
Verified date April 2023
Source Groupe Hospitalier Pitie-Salpetriere
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

Description:

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation. Other outcomes of interest include: acute kidney injury, encephalopathy, need for intensive care unit transfers.

Recruitment information / eligibility
Status Completed
Enrollment 400
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - admitted for severe Covid-19 pneumonia (i.e. requiring O2-support more than 6L/min with SpO2<96%) Exclusion Criteria: - patients who were previously in ICU - patients already hospitalized prior to study start date - patients in palliative care - lack of consent

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Centre Hospitalier Intercommunal Robert Ballanger Aulnay-sous-Bois
France Centre Hospitalier Intercommunal Le Raincy-Montfermeil Montfermeil

Sponsors (4)
Lead Sponsor Collaborator
Groupe Hospitalier Pitie-Salpetriere Centre Hospitalier Intercommunal Montfermeil-Le Raincy, Centre Hospitalier Intercommunal Robert Ballanger, CMC Ambroise Paré

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Composite of death and mechanical ventilation Composite of death and mechanical ventilation (i.e. intubation) 14-days follow-up
Secondary Death Death 14-days follow-up
Secondary Mechanical ventilation Enabled by intubation 14-days follow-up
Secondary Composite of death and mechanical ventilation Composite of death and mechanical ventilation 28-days follow-up
Secondary World Health Organization score World Health Organization score 14-days follow-up
Secondary World Health Organization score World Health Organization score 28-days follow-up
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure